Company news
Volitionrx Limited (AMEX:VNRX) news
Every Volitionrx Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
August 26, 2026
VolitionRx : Announces Second Quarter 2026 Financial Results and Business Update
August 13, 2026
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
August 12, 2026
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
August 12, 2026
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
August 5, 2026
Volition Advances Nu.Q® NETs Platform Towards Commercialization
July 30, 2026
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
July 7, 2026
VolitionRx Announces Collaboration with Sysmex
June 17, 2026
VolitionRx Announces Pricing of $4.6 Million Public Offering
June 7, 2026
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
June 3, 2026
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
May 27, 2026
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
May 14, 2026
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
May 11, 2026
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
May 6, 2026
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
April 29, 2026
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
April 23, 2026
Volition Launches rNuQ™ Webshop Broadening Product Range
April 20, 2026
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
March 31, 2026
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
March 30, 2026
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
March 26, 2026
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
March 25, 2026
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
March 18, 2026
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
March 6, 2026
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution
February 25, 2026
Volition Announces the Appointment of New Distributor for Nu.Q® Discover
February 10, 2026
VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
February 9, 2026
Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation
February 4, 2026
VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays
January 30, 2026
Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
January 27, 2026
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
January 20, 2026
Volition Sponsors Symposium at Veterinary Meeting and Expo
January 16, 2026
VolitionRx Secures $2.0 Million in Funding
January 8, 2026
VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
January 8, 2026
Volition Issues Business Review 2025
December 17, 2025
Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
December 11, 2025
Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
December 8, 2025
VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detecti...
December 4, 2025
VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
November 25, 2025
VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
November 13, 2025
VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
November 10, 2025
Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
October 17, 2025
VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants
October 10, 2025
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
October 9, 2025
Volition Sponsors Upcoming GenomeWeb Webinar
October 2, 2025
Volition Signs Co-Marketing and Services Agreement with Hologic
September 29, 2025
Volition Signs First Human Out Licensing Deal
September 9, 2025
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
August 14, 2025
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
August 8, 2025
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
August 4, 2025
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
July 16, 2025